Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.74% | 66.86% | 96.43% | 84.95% | 149.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.74% | 66.86% | 96.43% | 84.95% | 149.35% |
| Cost of Revenue | 80.74% | 108.78% | 197.18% | 160.39% | 132.99% |
| Gross Profit | 4.53% | 57.36% | 82.75% | 69.13% | 152.73% |
| SG&A Expenses | 6.19% | 7.61% | 34.42% | 10.17% | 45.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.25% | 34.13% | 55.97% | 38.23% | 52.48% |
| Operating Income | -6.03% | 1,528.74% | 1,386.07% | 225.26% | 578.49% |
| Income Before Tax | 5.43% | 530.43% | 9,460.35% | 183.08% | 358.20% |
| Income Tax Expenses | -15,348.00% | -56.95% | -1.39% | 77.06% | -516.75% |
| Earnings from Continuing Operations | 640.51% | 327.74% | 1,228.66% | 322.56% | 362.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 640.51% | 327.74% | 1,228.66% | 322.56% | 362.33% |
| EBIT | -6.03% | 1,528.74% | 1,386.07% | 225.26% | 578.49% |
| EBITDA | -5.63% | 10,979.82% | 768.76% | 259.60% | 706.75% |
| EPS Basic | 627.34% | 322.68% | 1,201.71% | 317.33% | 356.64% |
| Normalized Basic EPS | -9.12% | 520.95% | 15,429.41% | 161.46% | 392.07% |
| EPS Diluted | 633.45% | 318.85% | 1,172.00% | 310.82% | 346.29% |
| Normalized Diluted EPS | -7.95% | 506.68% | 14,838.24% | 159.64% | 379.52% |
| Average Basic Shares Outstanding | 1.81% | 2.28% | 2.48% | 2.41% | 2.22% |
| Average Diluted Shares Outstanding | 0.50% | 5.86% | 6.59% | 5.55% | 6.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |